Laurus Labs Q2 FY26: Strong CDMO & Generics Tailwinds Lift Profit Multi-fol

delivered a standout Q2 this fiscal, with notable gains across profit, revenue, and margins. Revenue rose by around 35 % YoY, powered by both its CDMO (Contract Development & Manufacturing Organization) segment and its generics business. Net profit surged dramatically — nearly nine-fold — as operational leverage kicked in. The CDMO arm showed striking growth, particularly in small molecules and late-phase/commercial deliveries, contributing meaningfully to overall revenues. Generics too held up well, with solid demand for developed-market and ARV (anti-retroviral) products. Margins expanded sharply: EBITDA rose by over 130 % YoY, with margin gains reflecting a favorable mix and efficiency gains. However, part of the uplift may be attributable to a low-base effect from the prior year, which makes the YoY comparison steeper. Still, the scale and mix of growth suggest this isn’t just optics — Laurus appears to be executing well on both its specialty manufacturing (CDMO) strategy and its generic product lines. What to Watch Going Forward: * Will the CDMO order funnel stay robust and ramp further into commercial phase deliveries? * Can Laurus sustain margin expansion as scale grows, and isn’t dragged down by higher input or regulatory costs? * Are its generics markets showing structural tailwinds, or are there risks of competition or regulatory pressure? * How it uses its strengthened profitability — reinvestment, R&D, capacity expansion, dividend or other capital allocation. In short, Laurus Labs has shown that its CDMO + generics play can deliver real operational leverage. The results offer reason for optimism, but sustaining growth while controlling risk will determine if this is a pivot or simply a strong quarter. Source: The Hindu No Recommendations